Maraviroc: pharmacokinetics and drug interactions.

摘要: Maraviroc is a potent selective CCR5 antagonist and the first of this new class oral agents to be approved for treatment CCR5-tropic HIV type-1. extensively metabolized by CYP3A4, with renal clearance accounting approximately 23% total clearance. The half-life maraviroc 16 h. does not inhibit any major CYP450 enzymes at clinically relevant doses it has shown effects on plasma concentrations other agents; hence, no dose adjustments coadministered are required. exposure altered that modulate activity CYP3A4 and, in some circumstances, adjustment necessary. This article aims review all pharmacokinetic drug interaction data available maraviroc, provide comprehensive summary recommendations when from classes antiretroviral therapy as well commonly agents.